The announcement came just weeks after an FDA subcommittee voted in favor of approval. 

The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.

The two anticoagulants are associated with similar mortality rates. However, a new meta-analysis in Circulation may have cardiologists favoring bivalirudin over heparin. 

Novo Nordisk is working with Valo Health to identify potential new treatments for cardiometabolic conditions. If it proves to be a fruitful collaboration, the initial payment of $60 million will be just the beginning. 

Researchers examined two-year data from transfemoral TAVR patients treated with low-dose aspirin and 30 days of warfarin or just aspirin on its own. 

The popular SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, has already been approved by the FDA to treat type 2 diabetes and heart failure.

The biggest differences between the two treatment options were major bleeding events and all-cause mortality. There was no significant difference when it came to stroke risk. 

Access to cannabis is skyrocketing across the United States, but much more research is still needed on its long-term side effects.